nodes	percent_of_prediction	percent_of_DWPC	metapath
Oritavancin—Allergic cutaneous angiitis—Sorafenib—thyroid cancer	0.0621	0.0621	CcSEcCtD
Oritavancin—Leukocytoclastic vasculitis—Sorafenib—thyroid cancer	0.0403	0.0403	CcSEcCtD
Oritavancin—Bilirubin total increased—Epirubicin—thyroid cancer	0.0364	0.0364	CcSEcCtD
Oritavancin—Bilirubin total increased—Doxorubicin—thyroid cancer	0.0337	0.0337	CcSEcCtD
Oritavancin—Cellulitis—Vandetanib—thyroid cancer	0.0322	0.0322	CcSEcCtD
Oritavancin—Blood bilirubin increased—Vandetanib—thyroid cancer	0.031	0.031	CcSEcCtD
Oritavancin—Hypoglycaemia—Vandetanib—thyroid cancer	0.0218	0.0218	CcSEcCtD
Oritavancin—Blood bilirubin increased—Sorafenib—thyroid cancer	0.0209	0.0209	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.0187	0.0187	CcSEcCtD
Oritavancin—Bronchospasm—Vandetanib—thyroid cancer	0.0181	0.0181	CcSEcCtD
Oritavancin—Infestation NOS—Vandetanib—thyroid cancer	0.0164	0.0164	CcSEcCtD
Oritavancin—Infestation—Vandetanib—thyroid cancer	0.0164	0.0164	CcSEcCtD
Oritavancin—Erythema multiforme—Vandetanib—thyroid cancer	0.0139	0.0139	CcSEcCtD
Oritavancin—Cardiac disorder—Vandetanib—thyroid cancer	0.0136	0.0136	CcSEcCtD
Oritavancin—Mediastinal disorder—Vandetanib—thyroid cancer	0.0133	0.0133	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.0129	0.0129	CcSEcCtD
Oritavancin—Malnutrition—Vandetanib—thyroid cancer	0.0128	0.0128	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.0126	0.0126	CcSEcCtD
Oritavancin—Infestation NOS—Sorafenib—thyroid cancer	0.011	0.011	CcSEcCtD
Oritavancin—Infestation—Sorafenib—thyroid cancer	0.011	0.011	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.0108	0.0108	CcSEcCtD
Oritavancin—Infection—Vandetanib—thyroid cancer	0.0104	0.0104	CcSEcCtD
Oritavancin—Nervous system disorder—Vandetanib—thyroid cancer	0.0102	0.0102	CcSEcCtD
Oritavancin—Skin disorder—Vandetanib—thyroid cancer	0.0101	0.0101	CcSEcCtD
Oritavancin—Connective tissue disorder—Sorafenib—thyroid cancer	0.00975	0.00975	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00952	0.00952	CcSEcCtD
Oritavancin—Erythema multiforme—Sorafenib—thyroid cancer	0.00938	0.00938	CcSEcCtD
Oritavancin—Abscess—Epirubicin—thyroid cancer	0.00922	0.00922	CcSEcCtD
Oritavancin—Cardiac disorder—Sorafenib—thyroid cancer	0.0092	0.0092	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00902	0.00902	CcSEcCtD
Oritavancin—Immune system disorder—Sorafenib—thyroid cancer	0.00896	0.00896	CcSEcCtD
Oritavancin—Mediastinal disorder—Sorafenib—thyroid cancer	0.00894	0.00894	CcSEcCtD
Oritavancin—Malnutrition—Sorafenib—thyroid cancer	0.00863	0.00863	CcSEcCtD
Oritavancin—Abscess—Doxorubicin—thyroid cancer	0.00854	0.00854	CcSEcCtD
Oritavancin—Extravasation—Epirubicin—thyroid cancer	0.00837	0.00837	CcSEcCtD
Oritavancin—Cellulitis—Epirubicin—thyroid cancer	0.00803	0.00803	CcSEcCtD
Oritavancin—Anaemia—Sorafenib—thyroid cancer	0.00798	0.00798	CcSEcCtD
Oritavancin—Angioedema—Sorafenib—thyroid cancer	0.00789	0.00789	CcSEcCtD
Oritavancin—Hyperuricaemia—Epirubicin—thyroid cancer	0.00787	0.00787	CcSEcCtD
Oritavancin—Extravasation—Doxorubicin—thyroid cancer	0.00774	0.00774	CcSEcCtD
Oritavancin—Blood bilirubin increased—Epirubicin—thyroid cancer	0.00772	0.00772	CcSEcCtD
Oritavancin—Blood uric acid increased—Epirubicin—thyroid cancer	0.00743	0.00743	CcSEcCtD
Oritavancin—Cellulitis—Doxorubicin—thyroid cancer	0.00743	0.00743	CcSEcCtD
Oritavancin—Pruritus—Vandetanib—thyroid cancer	0.00739	0.00739	CcSEcCtD
Oritavancin—Myalgia—Sorafenib—thyroid cancer	0.00735	0.00735	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0073	0.0073	CcSEcCtD
Oritavancin—Hyperuricaemia—Doxorubicin—thyroid cancer	0.00728	0.00728	CcSEcCtD
Oritavancin—Diarrhoea—Vandetanib—thyroid cancer	0.00715	0.00715	CcSEcCtD
Oritavancin—Blood bilirubin increased—Doxorubicin—thyroid cancer	0.00714	0.00714	CcSEcCtD
Oritavancin—Infection—Sorafenib—thyroid cancer	0.007	0.007	CcSEcCtD
Oritavancin—Nervous system disorder—Sorafenib—thyroid cancer	0.00691	0.00691	CcSEcCtD
Oritavancin—Dizziness—Vandetanib—thyroid cancer	0.00691	0.00691	CcSEcCtD
Oritavancin—Blood uric acid increased—Doxorubicin—thyroid cancer	0.00688	0.00688	CcSEcCtD
Oritavancin—Skin disorder—Sorafenib—thyroid cancer	0.00684	0.00684	CcSEcCtD
Oritavancin—Vomiting—Vandetanib—thyroid cancer	0.00664	0.00664	CcSEcCtD
Oritavancin—Rash—Vandetanib—thyroid cancer	0.00659	0.00659	CcSEcCtD
Oritavancin—Dermatitis—Vandetanib—thyroid cancer	0.00658	0.00658	CcSEcCtD
Oritavancin—Headache—Vandetanib—thyroid cancer	0.00654	0.00654	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00642	0.00642	CcSEcCtD
Oritavancin—Nausea—Vandetanib—thyroid cancer	0.0062	0.0062	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00608	0.00608	CcSEcCtD
Oritavancin—Urticaria—Sorafenib—thyroid cancer	0.0056	0.0056	CcSEcCtD
Oritavancin—Hypoglycaemia—Epirubicin—thyroid cancer	0.00543	0.00543	CcSEcCtD
Oritavancin—Hypersensitivity—Sorafenib—thyroid cancer	0.00519	0.00519	CcSEcCtD
Oritavancin—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00502	0.00502	CcSEcCtD
Oritavancin—Pruritus—Sorafenib—thyroid cancer	0.00499	0.00499	CcSEcCtD
Oritavancin—Diarrhoea—Sorafenib—thyroid cancer	0.00482	0.00482	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00477	0.00477	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00467	0.00467	CcSEcCtD
Oritavancin—Dizziness—Sorafenib—thyroid cancer	0.00466	0.00466	CcSEcCtD
Oritavancin—Eosinophilia—Epirubicin—thyroid cancer	0.00453	0.00453	CcSEcCtD
Oritavancin—Vomiting—Sorafenib—thyroid cancer	0.00448	0.00448	CcSEcCtD
Oritavancin—Rash—Sorafenib—thyroid cancer	0.00444	0.00444	CcSEcCtD
Oritavancin—Dermatitis—Sorafenib—thyroid cancer	0.00444	0.00444	CcSEcCtD
Oritavancin—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00441	0.00441	CcSEcCtD
Oritavancin—Headache—Sorafenib—thyroid cancer	0.00441	0.00441	CcSEcCtD
Oritavancin—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00432	0.00432	CcSEcCtD
Oritavancin—Eosinophilia—Doxorubicin—thyroid cancer	0.0042	0.0042	CcSEcCtD
Oritavancin—Nausea—Sorafenib—thyroid cancer	0.00419	0.00419	CcSEcCtD
Oritavancin—Infestation NOS—Epirubicin—thyroid cancer	0.00408	0.00408	CcSEcCtD
Oritavancin—Infestation—Epirubicin—thyroid cancer	0.00408	0.00408	CcSEcCtD
Oritavancin—Infestation—Doxorubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Oritavancin—Infestation NOS—Doxorubicin—thyroid cancer	0.00378	0.00378	CcSEcCtD
Oritavancin—Oedema peripheral—Epirubicin—thyroid cancer	0.00361	0.00361	CcSEcCtD
Oritavancin—Connective tissue disorder—Epirubicin—thyroid cancer	0.0036	0.0036	CcSEcCtD
Oritavancin—Erythema multiforme—Epirubicin—thyroid cancer	0.00347	0.00347	CcSEcCtD
Oritavancin—Cardiac disorder—Epirubicin—thyroid cancer	0.0034	0.0034	CcSEcCtD
Oritavancin—Oedema peripheral—Doxorubicin—thyroid cancer	0.00334	0.00334	CcSEcCtD
Oritavancin—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00333	0.00333	CcSEcCtD
Oritavancin—Immune system disorder—Epirubicin—thyroid cancer	0.00331	0.00331	CcSEcCtD
Oritavancin—Mediastinal disorder—Epirubicin—thyroid cancer	0.0033	0.0033	CcSEcCtD
Oritavancin—Erythema multiforme—Doxorubicin—thyroid cancer	0.00321	0.00321	CcSEcCtD
Oritavancin—Malnutrition—Epirubicin—thyroid cancer	0.00319	0.00319	CcSEcCtD
Oritavancin—Cardiac disorder—Doxorubicin—thyroid cancer	0.00315	0.00315	CcSEcCtD
Oritavancin—Immune system disorder—Doxorubicin—thyroid cancer	0.00306	0.00306	CcSEcCtD
Oritavancin—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00306	0.00306	CcSEcCtD
Oritavancin—Malnutrition—Doxorubicin—thyroid cancer	0.00295	0.00295	CcSEcCtD
Oritavancin—Anaemia—Epirubicin—thyroid cancer	0.00295	0.00295	CcSEcCtD
Oritavancin—Anaemia—Doxorubicin—thyroid cancer	0.00273	0.00273	CcSEcCtD
Oritavancin—Myalgia—Epirubicin—thyroid cancer	0.00272	0.00272	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0027	0.0027	CcSEcCtD
Oritavancin—Infection—Epirubicin—thyroid cancer	0.00259	0.00259	CcSEcCtD
Oritavancin—Nervous system disorder—Epirubicin—thyroid cancer	0.00255	0.00255	CcSEcCtD
Oritavancin—Tachycardia—Epirubicin—thyroid cancer	0.00254	0.00254	CcSEcCtD
Oritavancin—Skin disorder—Epirubicin—thyroid cancer	0.00253	0.00253	CcSEcCtD
Oritavancin—Myalgia—Doxorubicin—thyroid cancer	0.00251	0.00251	CcSEcCtD
Oritavancin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0025	0.0025	CcSEcCtD
Oritavancin—Infection—Doxorubicin—thyroid cancer	0.00239	0.00239	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00237	0.00237	CcSEcCtD
Oritavancin—Nervous system disorder—Doxorubicin—thyroid cancer	0.00236	0.00236	CcSEcCtD
Oritavancin—Tachycardia—Doxorubicin—thyroid cancer	0.00235	0.00235	CcSEcCtD
Oritavancin—Skin disorder—Doxorubicin—thyroid cancer	0.00234	0.00234	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00225	0.00225	CcSEcCtD
Oritavancin—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.0022	0.0022	CcSEcCtD
Oritavancin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00208	0.00208	CcSEcCtD
Oritavancin—Urticaria—Epirubicin—thyroid cancer	0.00207	0.00207	CcSEcCtD
Oritavancin—Hypersensitivity—Epirubicin—thyroid cancer	0.00192	0.00192	CcSEcCtD
Oritavancin—Urticaria—Doxorubicin—thyroid cancer	0.00191	0.00191	CcSEcCtD
Oritavancin—Pruritus—Epirubicin—thyroid cancer	0.00184	0.00184	CcSEcCtD
Oritavancin—Diarrhoea—Epirubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Oritavancin—Hypersensitivity—Doxorubicin—thyroid cancer	0.00178	0.00178	CcSEcCtD
Oritavancin—Dizziness—Epirubicin—thyroid cancer	0.00172	0.00172	CcSEcCtD
Oritavancin—Pruritus—Doxorubicin—thyroid cancer	0.0017	0.0017	CcSEcCtD
Oritavancin—Vomiting—Epirubicin—thyroid cancer	0.00166	0.00166	CcSEcCtD
Oritavancin—Diarrhoea—Doxorubicin—thyroid cancer	0.00165	0.00165	CcSEcCtD
Oritavancin—Rash—Epirubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Oritavancin—Dermatitis—Epirubicin—thyroid cancer	0.00164	0.00164	CcSEcCtD
Oritavancin—Headache—Epirubicin—thyroid cancer	0.00163	0.00163	CcSEcCtD
Oritavancin—Dizziness—Doxorubicin—thyroid cancer	0.00159	0.00159	CcSEcCtD
Oritavancin—Nausea—Epirubicin—thyroid cancer	0.00155	0.00155	CcSEcCtD
Oritavancin—Vomiting—Doxorubicin—thyroid cancer	0.00153	0.00153	CcSEcCtD
Oritavancin—Rash—Doxorubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Oritavancin—Dermatitis—Doxorubicin—thyroid cancer	0.00152	0.00152	CcSEcCtD
Oritavancin—Headache—Doxorubicin—thyroid cancer	0.00151	0.00151	CcSEcCtD
Oritavancin—Nausea—Doxorubicin—thyroid cancer	0.00143	0.00143	CcSEcCtD
